CYLD promotes the transdifferentiation of AFs by directly binding to Nox4 through the USP structural domain, which plays a role in vascular remodeling, and CYLD can be used as a new target for vascular anti-inflammatory therapy for diseases such as abdominal aortic aneurysms [91]. Here, CYLD is linked to abdominal aortic aneurysm.